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Abstract
Background: Current clinical assessments of people with multiple sclerosis are episodic and may miss critical features of
functional fluctuations between visits.
Objective: The goal of the research was to assess the feasibility of remote active testing and passive monitoring using smartphones
and smartwatch technology in people with multiple sclerosis with respect to adherence and satisfaction with the FLOODLIGHT
test battery.
Methods: People with multiple sclerosis (aged 20 to 57 years; Expanded Disability Status Scale 0-5.5; n=76) and healthy
controls (n=25) performed the FLOODLIGHT test battery, comprising active tests (daily, weekly, every two weeks, or on demand)
and passive monitoring (sensor-based gait and mobility) for 24 weeks using a smartphone and smartwatch. The primary analysis
assessed adherence (proportion of weeks with at least 3 days of completed testing and 4 hours per day passive monitoring) and
questionnaire-based satisfaction. In-clinic assessments (clinical and magnetic resonance imaging) were performed.
Results: People with multiple sclerosis showed 70% (16.68/24 weeks) adherence to active tests and 79% (18.89/24 weeks) to
passive monitoring; satisfaction score was on average 73.7 out of 100. Neither adherence nor satisfaction was associated with
specific population characteristics. Test-battery assessments had an at least acceptable impact on daily activities in over 80%
(61/72) of people with multiple sclerosis.
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Conclusions: People with multiple sclerosis were engaged and satisfied with the FLOODLIGHT test battery. FLOODLIGHT
sensor-based measures may enable continuous assessment of multiple sclerosis disease in clinical trials and real-world settings.
Trial Registration: ClinicalTrials.gov: NCT02952911; https://clinicaltrials.gov/ct2/show/NCT02952911
(J Med Internet Res 2019;21(8):e14863)  doi: 10.2196/14863
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Introduction
Disease progression throughout the clinical course of multiple
sclerosis (MS) is measured using clinician-reported outcomes,
most commonly the Expanded Disability Status Scale (EDSS)
[1], magnetic resonance imaging (MRI), and patient-reported
outcomes (PROs). Conventional assessment of the clinical
course of MS relies on relapse-associated and periodic in-clinic
visits. However, the current intermittently conducted
clinic-based outcome measures in MS have limitations in
studying the insidiously subtle progression in MS and may fail
to comprehensively capture transient symptomatic and
performance fluctuations that affect people with multiple
sclerosis.
The ability of consumer wearable technology to measure
functional impairment associated with various neurological
disease symptoms through smartphone-based assessments is an
important area of research [2-5]. Smartphones as vehicles for
sensor-based technologies offer the potential for enhanced active
and passive real-time data capture that may fundamentally shift
traditional paradigms of clinical monitoring [6-9]. A recent
large-scale study demonstrated that more than 95% of people
with multiple sclerosis have access to a mobile device and most
use it routinely [10]. Recently published studies have described
the use of technologies in developing tools to assess people with
multiple sclerosis [7,9,11-13]. In a recent study, it was reported
that both healthy participants and people with multiple sclerosis
were capable of completing daily tasks on a smartphone for 1
year [7]. Collection of data on a variety of cognitive and motor
tests via the smartphone may represent a feasible way to gather
highly granular data to accurately describe the MS disease
course outside of the clinic [7].
The FLOODLIGHT study [NCT02952911] was a prospective
pilot study to assess the feasibility of remote measurements
using smartphones and smartwatches in people with multiple
sclerosis and healthy controls (HCs). The smartwatch and
smartphone contained apps that prompted the user to perform
various assessments and protocols, referred to as active tests.
The app also passively recorded sensor data during daily life,
referred to as passive monitoring. The novel smartphone- and
smartwatch-based FLOODLIGHT active tests were developed
to be self-administered by people with multiple sclerosis to
capture MS symptoms, including hand motor function, gait and
posture, mood, and cognitive impairment.
The primary objectives of the FLOODLIGHT study, which
began in November 2016, were to evaluate participant adherence
to smartphone- and smartwatch-based assessments and collect
feedback from people with multiple sclerosis and HCs on the
smartphone and smartwatch schedule of assessments and its
impact on their daily activities using a patient satisfaction
questionnaire. Other objectives of the study, which will be
addressed in subsequent publications, are to determine the
association between exploratory sensor-based outcomes derived
from the respective components of the FLOODLIGHT test
battery and conventional MS clinical outcomes and explore
whether the FLOODLIGHT test battery can differentiate
between participants with and without MS.
Methods
Trial Design and Participants
After providing written informed consent, people with multiple
sclerosis and HCs, preferentially partners or cohabitants, were
evaluated for eligibility for enrollment in the FLOODLIGHT
study. Eligibility criteria for people with multiple sclerosis
included the ability to comply with the study protocol, age 18
to 55 years, diagnosis of MS (2010 revised McDonald criteria,
treated or untreated) [14], EDSS score 0 to 5.5 (inclusive), and
weight from 99 to 243 lbs (45 to 110 kg). An EDSS score of
5.5 as a maximum limit was meant to ensure any patient with
relapsing or progressive MS would not have any significant
difficulty in participating in the proposed testing as per study
protocol. Further details on eligibility criteria are provided in
Multimedia Appendix 1.
This study was conducted at two sites in two countries with a
total of 76 people with multiple sclerosis and 25 HCs; 60 people
with multiple sclerosis and 20 HCs were recruited from the
Multiple Sclerosis Centre of Catalonia, Vall d’Hebron
University Hospital, Barcelona, Spain, and 16 people with
multiple sclerosis and 5 HCs were recruited from the University
of California, San Francisco, California.
The protocol, informed consent forms, any information given
to the participants, and relevant supporting information were
reviewed and approved by the institutional review board/ethics
committee before the study was initiated. Confidentiality was
maintained by assigning each participant enrolled in the study
a unique identification number.
Study Design
The FLOODLIGHT study combines continuous sensor data
capture with smartphones and smartwatches and standard
clinical outcome measures. Eligible people with multiple
sclerosis and HCs were enrolled in the study and assessed
clinically at the enrollment visit, week 12, and termination visit
(week 24). In addition, participants were asked to perform a set
of daily active tests and contribute sensor data via passive
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monitoring with smartphone and smartwatches over a period of 24 weeks (Figure 1).
Figure 1. FLOODLIGHT study design. PRO: patient-reported outcome. "a" indicates that active tests were administered weekly or every two weeks
(see next figure for schedule). "b" indicates that brain magnetic resonance imaging was performed in people with multiple sclerosis.
In-Clinic Assessments
At each scheduled in-clinic visit (enrollment, week 12, and
week 24), the following reference clinical tests were performed
for all participants: 9-Hole Peg Test (9HPT), oral version of
Symbol Digit Modalities Test (SDMT) [15-17], Timed 25-Foot
Walk (T25FW) test, Berg Balance Scale (BBS) [18], Fatigue
Scale for Motor and Cognitive Functions (FSMC) [19], and
Patient Health Questionnaire–9 (PHQ-9) [20]. For people with
multiple sclerosis only, disability was measured by EDSS [1],
Patient Determined Disease Steps (PDDS) [21], and Multiple
Sclerosis Impact Scale–29 (MSIS-29; version 2) [22-24]. While
performing some of the in-clinic tests, people with multiple
sclerosis and HCs were asked to carry or wear the smartphone
and smartwatch to collect sensor data alongside the in-clinic
measures. On the scheduled in-clinic visits, the smartphone and
smartwatch FLOODLIGHT active tests were performed under
investigator supervision. The satisfaction questionnaire
(Multimedia Appendix 2) assessed people with multiple
sclerosis’ and HCs’ experience regarding smartphone and
smartwatch use and its impact on their daily activities at the
week 12 visit and at the study termination/early discontinuation
visit. Brain MRI was performed in people with multiple sclerosis
at the enrollment visit and at week 24.
Smartphone and Smartwatch Testing
At the enrollment visit, people with multiple sclerosis and HCs
were provided with the FLOODLIGHT solution that included
a smartphone and smartwatch preconfigured so participants
could only run the FLOODLIGHT software. A belt bag was
also provided for participants to carry their smartphone in an
anterior medial position. The smartphone and smartwatch pair
contained preinstalled apps that prompted the user to perform
various assessments, referred to as active tests. The apps also
passively recorded sensor data, referred to as passive monitoring.
At the enrollment visit, participants received training on the use
of the smartphone and smartwatch and were provided with
supporting content to help them complete the tests successfully.
Participants were instructed to complete the active tests at
approximately the same time each day and carry the smartphone
and smartwatch throughout the day, recharging the devices
overnight. Data transfer from the smartphone and smartwatch
is described in Multimedia Appendix 1.
FLOODLIGHT Active Tests
People with multiple sclerosis and HCs were asked to perform
various active tests (daily, weekly, every two weeks, or on
demand) via the smartphone (Figure 2 and Table 1). These novel
active tests were developed to be self-administered by people
with multiple sclerosis to capture MS symptoms. A range of
clinical and sensor-based assessments were chosen to capture
the most prominent symptoms of MS from a broad spectrum
of symptoms. People with multiple sclerosis and HCs were
required to wear the smartwatch throughout the active tests.
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Figure 2. FLOODLIGHT active tests and their schedule frequency. DMQ: Daily Mood Question; MSIS-29: Multiple Sclerosis Impact Scale–29; SBT:
Static Balance Test; SDMT: Symbol Digit Modalities Test; ST: Symptom Tracker; 2MWT: Two-Minute Walk Test; 5UTT: 5 U-Turn Test.
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Table 1. FLOODLIGHT active tests.
Short descriptionDomain and test
Daily hand motor function testsa
The aim of the DaS Test is to assess fine finger/manual dexterity while the participants are instructed to hold the
mobile device in the untested hand and draw on the smartphone touchscreen six prewritten alternating shapes of
increasing complexity (linear, rectangular, circular, sinusoidal, and spiral) with the second finger of the tested hand
as fast and as accurately as possible within a maximum time (30 seconds for each of the two attempts per shape).
Draw a Shape (DaS) Test
The aim of the Pinching Test is to assess fine pinching/grasping dexterity while the participants are instructed to
hold the mobile device in the untested hand and touch the screen with two fingers from the tested hand (thumb +
second or thumb + third finger preferred) to squeeze/pinch as many round shapes (ie, tomatoes) as they can during
30 seconds.
Pinching Test 
Daily gait testsb
Participants are instructed to walk as fast and as long as they can for 2 minutes but walk safely. The 2MWT is a
simple test that is required to be performed on an even ground in a place where participants have identified they
could walk straight for as far as ≥200 meters without U-turns. Participants are allowed to wear regular footwear
and an assistive device and/or orthotic as needed.
Two-Minute Walk Test
(2MWT)
The aim of this test is to assess difficulties or unusual patterns in performing U-turns while walking on a short
distance at comfortable pace. The 5UTT can be performed indoors or outdoors, on an even ground where participants
are instructed to walk safely and perform five successive U-turns going back and forward between two points a
few meters apart for 1 minute. Participants are allowed to wear regular footwear and an assistive device and/or
orthotic as needed.
5 U-Turn Test (5UTT) 
Participants are asked to stand still unsupported for 30 seconds with relaxed arms straight alongside the body if
possible.
Static Balance Test (SBT) 
Weekly cognitive test
The aim of SDMT testing is to detect impairment of key neurocognitive functions that underlie many substitution
tasks.
Electronic version of the
Symbol Digit Modalities
Test (SDMT) [15-17]
Patient-reported outcomes
(PROs)
This test represents an assessment of participants’ perceived overall state by responding daily to the question “How
do you feel now?” on a 5-item Likert scale, ranging from excellent to horrible.
Daily Mood Question
(DMQ)
This questionnaire measures the physical and psychological impact of multiple sclerosis.Electronic version of the
Multiple Sclerosis Impact
Scale–29, version 2 (MSIS-
29) [22-24]; people with
multiple sclerosis only
 
Patients are asked if they experienced new or significantly worsening symptoms during the last 2 weeks. If yes,
onset of the symptoms and the patients’ perception to whether they think they experienced a relapse (yes, no, or
unsure) are recorded.
Multiple Sclerosis Symptom
Tracker (MSST); people
with multiple sclerosis only
 
aTests alternatingly performed with right and left hand; users are instructed on daily alternation.
bRecommended position of smartphone in an anterior medial position in the belt bag.
FLOODLIGHT Passive Monitoring
Passive monitoring collected metrics on gait and mobility
throughout the day in a continuous and unobtrusive manner.
Participants were instructed to carry their smartphone preferably
in an anterior medial position in a belt bag or, alternatively, in
their pocket and wear the smartwatch all day as they went about
their daily routine until the devices ran out of charge.
Statistical Analyses
The analyses of the primary objectives of this study were
descriptive. Statistical tests were exploratory and conducted at
the two-sided 5% significance level without adjustment for
multiple comparisons. The analyses were based on all enrolled
patients (full analysis set [FAS]). Patients who prematurely
withdrew from the study for any reason were still included in
the FAS. Supportive analyses of selected variables were carried
out in the per-protocol population, which included people with
multiple sclerosis who completed at least 1 week in the study
and did not discontinue due to an adverse event or a reason
unrelated to the use of the FLOODLIGHT solution (Multimedia
Appendix 3).
Adherence was evaluated for the following tests and test groups:
all FLOODLIGHT active tests, Two-Minute Walk Test
(2MWT), all active tests except 2MWT, smartphone use,
smartwatch use, and for the per-protocol population.
Adherence to active tests was measured as the proportion of
study weeks with at least 3 days of completed testing (study
co-primary endpoint). Adherence to sensor-based passive
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monitoring was measured as the proportion of study weeks with
at least 3 days of passive monitoring for at least 4 hours per day
while the devices were worn by the participant [25] (study
co-primary endpoint). Descriptive statistics of calculated
adherence were reported for all active tests, all active tests
except 2MWT, 2MWT, smartphone use, and smartwatch use.
Categorical and numeric variables with fewer than five values
were tested for association with adherence using the
Kruskal-Wallis test. The association between continuous
variables was assessed using the Spearman rank correlation.
Participant complete abandoning of active testing and passive
monitoring was also investigated in a time-to-event survival
analysis based on the Kaplan-Meier method along the
FLOODLIGHT study. The abandoning event was defined as
the last week in which the participant was adherent according
to the definitions above for active tests and passive monitoring.
Active tests performed on days of in-clinic visits were not
considered in the adherence calculation to focus the abandoning
analysis on the remote use. Participants leaving the study before
the terminal visit were considered as censored. The impact of
different characteristics on adherence was assessed using Cox
regression.
A satisfaction score was developed from the satisfaction
questionnaire (Multimedia Appendix 2) that sums the individual
answers to questions 1-7 and 10-12 rescaled to 0-100 from their
original Likert scale. An interquestion correlation analysis was
performed to ensure questions are equally correlated and can
be combined. Descriptive statistics of satisfaction score and
items are reported, along with covariate analyses of
demographics and disease state. Analysis of the change in
satisfaction score between week 12 and week 24 are reported
using the Wilcoxon signed-rank test.
Patient baseline characteristics incorporated as covariates in the
analysis of correlation with FLOODLIGHT adherence and
satisfaction outcomes were age, gender, body mass index, time
since first MS symptom onset, EDSS, T25FW time, 9HPT time,
and the oral SDMT correct responses. A descriptive analysis of
safety variables, including adverse events and serious adverse
events, was carried out in the FAS.
Results
Baseline Demographics and Characteristics
Participants’ baseline demographics for the FAS are described
in Table 2. There was an expected greater proportion of females
among the people with multiple sclerosis compared with HCs.
The majority (69/76, 91%) of people with multiple sclerosis
had relapsing-remitting MS (RRMS), with a mild EDSS score
(mean 2.4) and presumably “normal” hand/arm function based
on an upper limit of normal range defined as the average 9HPT
time for HCs plus two standard deviations [26] (Table 2).
Overall, 92% (70/76) of people with multiple sclerosis and 64%
(16/25) of HCs who enrolled in the FLOODLIGHT study
reached the week 24 visit. Reasons for discontinuation from the
study are described in Multimedia Appendix 3.
J Med Internet Res 2019 | vol. 21 | iss. 8 | e14863 | p. 6http://www.jmir.org/2019/8/e14863/
(page number not for citation purposes)
Midaglia et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 2. Demographics and characteristics of people with multiple sclerosis and healthy controls (HCs) at baseline.
HCs (n=25)People with multiple sclerosis (n=76)Parameter
34.9 (9.3)39.5 (7.9)Age (years), mean (SD)
7 (28)53 (70)Female, n (%)
Multiple sclerosis (MS) diagnosis, n (%)
—
a3 (4)Primary progressive multiple sclerosis
—4 (5)Secondary progressive multiple sclerosis
—69 (91)Relapsing-remitting multiple sclerosis
—11.3 (7.0)bTime since MS symptom onset (years), mean (SD)
—18 (24)Proportion of people with multiple sclerosis with ≥1 relapse in the past year, n (%)
—2.4 (1.4)Expanded Disability Status Scale, mean (SD)
—2 (3)dProportion of people with multiple sclerosis with ≥1 T1 Gdc-enhancing lesion, n (%)
—6.3 (7.5)fTotal FLAIRe lesion volume (mL), mean (SD)
9-Hole Peg Test (seconds), mean (SD)
18.9 (2.1)22.1 (4.6)gDominant hand
19.5 (2.0)22.8 (4.9)hNondominant hand
5.0 (1.0)6.0 (2.1)bTimed 25-Foot Walk (seconds), mean (SD)
63.8 (10.0)53.8 (11.8)bSymbol Digit Modalities Test (correct responses), mean (SD)
56.0 (0)j52.5 (5.7)iBerg Balance Scale, mean (SD)
—1.5 (1.6)Patient Determined Disease Steps, mean (SD)
25.5 (6.0)59.1 (22.7)gFatigue Scale for Motor and Cognitive Functions (total score), mean (SD)
2.4 (2.9)l8.3 (6.1)kPatient Health Questionnaire–9, mean (SD)
6 (24)46 (61)Participants with any previous medications, n (%)
Previous disease-modifying treatmentm, n (%)
—0 (0)Daclizumab (Zinbryta)
—12 (16)Glatiramer acetate (Copaxone)
—1 (1)Glatiramer acetate (Glatopa)
—4 (5)IFNn β-1a IMo (Avonex)
—5 (7)IFN β-1a SCp (Rebif)
—6 (8)IFN β-1b SC (Betaseron/Betaferon)
—1 (1)IFN β-1b SC (Extavia)
—2 (3)Pegylated IFN β-1a (Plegridy)
—9 (12)Dimethyl fumarate (Tecfidera)
—9 (12)Fingolimod (Gilenya)
—3 (4)Teriflunomide (Aubagio)
—2 (3)Alemtuzumab (Lemtrada)
—1 (1)Mitoxantrone (Novantrone)
—19 (25)Natalizumab (Tysabri)
—5 (7)Otherq
aNot applicable.
bn=75.
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cGd: gadolinium.
dn=68.
eFLAIR: fluid-attenuated inversion recovery.
fn=70.
gn=73.
hn=74.
in=71.
jn=22.
kn=60.
ln=20.
mTotal baseline disease-modifying treatment history.
nIFN: interferon.
oIM: intramuscular.
pSC: subcutaneous.
qHidroferol; Radiance study (RPC1063 versus IFN β-1a); Rituximab (Rituxan).
Adherence
Over a period of 18 months (November 2016-April 2018), more
than 6 terabytes of raw data were collected from 76 people with
multiple sclerosis and 25 HCs. Participants performed 67,544
active tests, of which 9787 were the 2MWT, and recorded
200,171 hours of passive monitoring, of which 113,165 hours
were captured with the smartwatch. Over 24 weeks, most
participants performed 5 to 7 active tests per week, including
the 2MWT (Figure 3). Adherence of people with multiple
sclerosis to completing active tests and passive monitoring was
good and remained stable over time after week 6 (Figures 4 and
5). Even in the last week of the 24-week study, participants
completed all active tests on average 4 out of 7 days per week
(Figure 4), and recorded at least 4 hours of data via passive
monitoring on average 4 out of 7 days per week (Figure 5). The
lowest average adherence over 24 weeks was observed for active
tests including the 2MWT and the 2MWT only, with participants
showing highest average adherence for passive monitoring
(Figure 6). A total of 70% (16.68/24 weeks) of participants were
adherent to all active tests, 75% (17.95/24 weeks) to all active
tests except 2MWT, 71% (17.13/24 weeks) to 2MWT, 79%
(18.89/24 weeks) to smartphone- or smartwatch-based passive
monitoring, 66% (15.74/24 weeks) to smartphone-based passive
monitoring, and 74% (17.69/24 weeks) to smartwatch-based
passive monitoring.
Figure 3. Adherence of people with multiple sclerosis to active tests for individual participants: number of performed active tests per week [level of
activity (light green: high; dark green/grey: low] over individual study weeks [columns]).
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Figure 4. Adherence of people with multiple sclerosis to active tests. 2MWT: Two-Minute Walk Test.
Figure 5. Adherence of people with multiple sclerosis to smartphone and smartwatch passive monitoring. Days with more than 4 hours of passive
monitoring on a device are considered as adherent.
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Figure 6. Adherence of people with multiple sclerosis to active tests and passive monitoring. The results of the time-to-event survival analysis based
on the Kaplan–Meier method along the FLOODLIGHT study. The abandoning event was defined as the last week in which the participant was adherent
according to the definitions for active tests and passive monitoring. Active tests performed on days of in-clinic visits were not considered in the adherence
calculation, to focus the abandoning analysis on the remote use. Participants leaving the study before the terminal visit were considered as censored.
2MWT: Two-Minute Walk Test.
Correlation was explored between adherence measures and
people with multiple sclerosis population characteristics. Only
disease duration showed significant small negative correlation
with measures of adherence (Spearman rank correlations;
2MWT adherence: –0.42, P<.001; smartphone passive
monitoring adherence: –0.29, P=.02; all active tests except
2MWT adherence: –0.37, P=.003; and smartwatch passive
monitoring adherence: –0.27, P=.04), indicating that disease
severity and demographics did not appear to play a significant
role in adherence.
Patient Satisfaction
The average overall satisfaction score among people with
multiple sclerosis who completed the study at week 12 (n=64)
was 74.1 out of a possible 100 and remained stable at week 24
(study termination/early discontinuation visit [n=68]) with 73.7
out of 100 (Wilcoxon signed-rank test P=.71). There was one
significant association between overall satisfaction score and
gender (P=.04). Individual questions from the satisfaction
questionnaire (Multimedia Appendix 2) were analyzed for their
association with people with multiple sclerosis population
characteristics, described in Multimedia Appendix 1.
Implications for the use of the FLOODLIGHT test battery in
people with multiple sclerosis were assessed from individual
questions from the patient satisfaction questionnaire. When
asked to rate the impact of the smartphone, smartwatch, and
active tests on daily living, more than 80% (61/72) of people
with multiple sclerosis perceived the FLOODLIGHT test battery
to have at least acceptable impact on daily activities (Figure 7).
Nearly 50% (32/71) of participants had no issue with any of the
active tests, and only one-third would prefer to avoid the 2MWT,
most likely due to increased burden from execution—for
example, having to find a place to perform the test or not
wanting to go outside in bad weather (Figure 8). Without
providing any data feedback to the people with multiple sclerosis
throughout the study, more than 60% (46/72) of participants
would have liked to continue using FLOODLIGHT “to
understand my MS better and improve my disease management”
(Figure 9). Approximately 90% (65/72) of people with multiple
sclerosis indicated their interest to see the results of the tests,
which will be addressed in future Roche-sponsored studies using
FLOODLIGHT (CONSONANCE [NCT03523858] and
FLOODLIGHT Open [floodlightopen.com]; Figure 10).
Analysis of patient responses to the satisfaction questionnaire
is described in Multimedia Appendix 1.
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Figure 7. Implications of FLOODLIGHT in people with multiple sclerosis for “impact on daily activities” from the patient satisfaction questionnaire.
Figure 8. Implications of FLOODLIGHT in people with multiple sclerosis for “avoiding one component of FLOODLIGHT" from the patient satisfaction
questionnaire. 2MWT: Two-Minute Walk Test.
Figure 9. Implications of FLOODLIGHT in people with multiple sclerosis for “desire to continue using the FLOODLIGHT app” from the patient
satisfaction questionnaire.
Figure 10. Implications of FLOODLIGHT in people with multiple sclerosis for “prefer to see results immediately to monitor” from the patient satisfaction
questionnaire.
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Discussion
Principal Findings
This study demonstrates that the use of smartphones and
smartwatches for remote daily active testing and continuous
passive monitoring is feasible over 6 months and provides
further support to earlier studies, which have shown that healthy
participants and people with multiple sclerosis were capable of
completing daily tasks on a smartphone [7]. This study provides
further evidence for the use of digital technology, including
smartphones, for data collection. Other studies in MS have used
smartphone apps to (1) assess steps when walking on a treadmill
[9]; (2) assess pain, fatigue, anxiety, and quality of life [13];
and (3) assess the feasibility of gathering passive and active
performance data [7]. Together with the current analyses, these
studies document the focus toward developing digital measures
to continuously monitor and assess the MS disease.
In this protocol, the FLOODLIGHT solution collected metrics
on cognition, mood, upper extremity function, and gait and
posture by instructing participants to perform a set of daily
active tests, which should take approximately 5 minutes in total
to complete and capture activity data via passive monitoring
over a period of 24 weeks. A previous study has shown that
51% of participants (22/38 of people with multiple sclerosis
and 17/38 of healthy participants) completed 12 months of daily
data collection, where participants were prompted to complete
one assigned test [7]. In the context of the FLOODLIGHT study,
we observed that overall adherence to active tests was 70%
(16.68/24 weeks), which appears to be higher than the adherence
of participants to 12 months of daily data collection (39/76,
51%) from Bove et al [7]. However, comparisons between the
studies are limited, as the study design and burden of testing
are different—for example, the app from Bove et al contained
19 different tests, of which participants were prompted to
complete one each day. As the FLOODLIGHT app was
integrated into standalone devices in this study, deployment of
the app on participants’ own mobile devices may increase
adherence because it removes the need to carry a separate,
dedicated device and decreases burden on the individual.
Limitations
As this study remains a pilot investigation designed to collect
first experiences from continuous sensor data capture, the main
limitation is the small sample size and short duration of
follow-up. Future ongoing FLOODLIGHT studies
(CONSONANCE and FLOODLIGHT Open) will collect longer
term data on smartphone-based sensor data capture in a larger
number of participants from a broader disability spectrum.
Additionally, whether physical and cognitive limitations in
people with secondary progressive MS (SPMS) and people with
primary progressive MS (PPMS) differentially impacts
adherence compared with people with relapsing MS (RMS)
cannot be gleaned from the current data set due to the low
numbers of advanced patients enrolled in the study; however,
this important question warrants future research exploring
remote monitoring in patients with more advanced MS. The
importance of continuous monitoring in RMS should also not
be overlooked, as the sensitivity of this novel approach aiming
at detecting progression in a real-world setting may provide an
earlier window into disease progression outside of the clinic.
Comparison With Prior Work
A recent study assessing the feasibility of the MS TeleCoach,
a novel intervention offering telemonitoring of fatigue and
telecoaching of physical activity in people with multiple
sclerosis, showed that participants were highly engaged, with
76% (57/75) of participants completing the study, and 91%
(21/23) of a subset of completers showing a median of quite
satisfied in the patient satisfaction questionnaire [27]. During
the 12-week study period, use of the MS TeleCoach improved
fatigue levels in people with multiple sclerosis with moderate
to severe fatigue, suggesting that implementation of digital
technologies can enhance patient performance. Together with
the data presented here, these results indicate that the use of
consumer devices by people with multiple sclerosis for sensor
data capture fulfills the prerequisites of people with multiple
sclerosis satisfaction and acceptable adherence to daily active
tests and passive monitoring for potential integration in
long-term clinical trials and treatment monitoring. Regarding
future studies, for example FLOODLIGHT Open, attempts will
be made to improve participant adherence throughout the study
by introducing controlled app variations, such as reminders,
types of achievements, and fun metrics.
Conclusions
In summary, these analyses showed that people with multiple
sclerosis are highly engaged with performing active tests and
capturing continuous data via passive monitoring and are
satisfied with the FLOODLIGHT test battery. Neither
satisfaction nor adherence showed strong correlation with study
population characteristics. More than 60% (46/72) of people
with multiple sclerosis indicated their interest to continue to
use FLOODLIGHT, and approximately 90% (65/72) wanted
to see the results of their tests in real time as biofeedback, which
was implemented in future studies using the FLOODLIGHT
solution. These findings indicate that smartphone-based
FLOODLIGHT outcomes may represent a promising avenue
to enable a more accurate and continuous assessment of MS
disease in clinical trials and real-world practice settings and
may eventually also contribute to informing and guiding clinical
research and clinical practice in the future.
Acknowledgments
We would like to thank all patients, their families, and the investigators who participated in this trial. This research was funded
by F Hoffmann–La Roche Ltd, Basel, Switzerland. We would like to thank the following employees from F Hoffmann–La Roche
Ltd who supported and contributed to the study: Atieh Bamdadian, Alessandro Barbato, Jan Beckmann, Sandro Fritz, Nicholas
Pierce Heinemeier, Timothy Kilchenmann, Lito Kriara, Bernd Laub, Grégoire Pointeau, Caroline Polakowska, Marcin Puhacz,
Cedric Simillion, Jens Schjodt-Eriksen, Jöerg Sprengel, Ralf Stubner, and Krzysztof Trybus. Writing and editorial assistance for
J Med Internet Res 2019 | vol. 21 | iss. 8 | e14863 | p. 12http://www.jmir.org/2019/8/e14863/
(page number not for citation purposes)
Midaglia et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
this manuscript was provided by Heather Latimer from Articulate Science, United Kingdom, and funded by F Hoffmann–La
Roche Ltd.
Qualified researchers may request access to individual patient-level data through the clinical study data request platform
(https://clinicalstudydatarequest.com). Further details on Roche’s criteria for eligible studies are available at
https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx. For further details on Roche’s Global Policy
on the Sharing of Clinical Information and how to request access to related clinical study documents, see
https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm.
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: F
Hoffmann–La Roche Ltd, Basel, Switzerland, provided financial support for the study and publication of this manuscript.
Conflicts of Interest
XM has received speaker honoraria and travel expense reimbursement for participation in scientific meetings, been a steering
committee member of clinical trials, or served on advisory boards of clinical trials for Actelion, Biogen, Celgene, Merck, Novartis,
Oryzon, Roche, Sanofi Genzyme, and Teva Pharmaceutical. JG has received grants or research support from Biogen, Genentech
Inc, and S3 Group and has received compensation for a nonbranded resident and fellow education seminar supported by Biogen.
SLH serves on the scientific advisory boards for Annexon, Symbiotix, Bionure, and Molecular Stethoscope, is on the board of
trustees for Neurona Therapeutics, and has received travel reimbursement and writing assistance from F Hoffmann–La Roche
Ltd for CD20-related meetings and presentations. LJ is an employee of Genentech Inc and a shareholder of F Hoffmann–La
Roche Ltd. MB, JS, and CG are employees and shareholders of F Hoffmann–La Roche Ltd. AS, FL, and JvB are employees of
F Hoffmann–La Roche Ltd. CB and ML are contractors for F Hoffmann–La Roche Ltd. SB was an employee of F Hoffmann–La
Roche Ltd during the completion of the work related to this manuscript. SB is now an employee of Biogen (Cambridge, MA),
which was not in any way associated with this study. LM and PM have nothing to disclose.
Multimedia Appendix 1
Additional trial information.
[PDF File (Adobe PDF File), 278KB-Multimedia Appendix 1]
Multimedia Appendix 2
Satisfaction questionnaire.
[PDF File (Adobe PDF File), 238KB-Multimedia Appendix 2]
Multimedia Appendix 3
Participant flow table.
[PDF File (Adobe PDF File), 138KB-Multimedia Appendix 3]
References
1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology
1983 Nov;33(11):1444-1452. [Medline: 6685237]
2. Bradshaw MJ, Farrow S, Motl RW, Chitnis T. Wearable biosensors to monitor disability in multiple sclerosis. Neurol Clin
Pract 2017 Aug;7(4):354-362. [doi: 10.1212/CPJ.0000000000000382] [Medline: 29185551]
3. Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, et al. e-Health and multiple sclerosis: An update. Mult
Scler 2018 Nov;24(13):1657-1664. [doi: 10.1177/1352458518799629] [Medline: 30231004]
4. Busis N. Mobile phones to improve the practice of neurology. Neurol Clin 2010 May;28(2):395-410. [doi:
10.1016/j.ncl.2009.11.001] [Medline: 20202500]
5. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, et al. Evaluation of smartphone-based
testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord 2018
Dec;33(8):1287-1297 [FREE Full text] [doi: 10.1002/mds.27376] [Medline: 29701258]
6. Prasad S, Ramachandran R, Jennings C. Development of smartphone technology to monitor disease progression in multiple
sclerosis. Neurology 2012 Apr 22;78(Meeting Abstracts 1):P01.144. [doi: 10.1212/WNL.78.1_MeetingAbstracts.P01.144]
7. Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, et al. Evaluating more naturalistic outcome measures:
a 1-year smartphone study in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015 Dec;2(6):e162 [FREE Full
text] [doi: 10.1212/NXI.0000000000000162] [Medline: 26516627]
8. Boukhvalova AK, Kowalczyk E, Harris T, Kosa P, Wichman A, Sandford MA, et al. Identifying and quantifying neurological
disability via smartphone. Front Neurol 2018;9:740 [FREE Full text] [doi: 10.3389/fneur.2018.00740] [Medline: 30233487]
J Med Internet Res 2019 | vol. 21 | iss. 8 | e14863 | p. 13http://www.jmir.org/2019/8/e14863/
(page number not for citation purposes)
Midaglia et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
9. Balto JM, Kinnett-Hopkins DL, Motl RW. Accuracy and precision of smartphone applications and commercially available
motion sensors in multiple sclerosis. Mult Scler J Exp Transl Clin 2016;2:2055217316634754 [FREE Full text] [doi:
10.1177/2055217316634754] [Medline: 28607720]
10. Haase R, Schultheiss T, Kempcke R, Thomas K, Ziemssen T. Modern communication technology skills of patients with
multiple sclerosis. Mult Scler 2013 Aug;19(9):1240-1241. [doi: 10.1177/1352458512471882] [Medline: 23388164]
11. Rudick RA, Miller D, Bethoux F, Rao SM, Lee J, Stough D, et al. The Multiple Sclerosis Performance Test (MSPT): an
iPad-based disability assessment tool. J Vis Exp 2014 Jun 30(88):e51318 [FREE Full text] [doi: 10.3791/51318] [Medline:
25046650]
12. Gholami F, Trojan DA, Kovecses J, Haddad WM, Gholami B. A Microsoft Kinect-based point-of-care gait assessment
framework for multiple sclerosis patients. IEEE J Biomed Health Inform 2017 Dec;21(5):1376-1385. [doi:
10.1109/JBHI.2016.2593692] [Medline: 27455529]
13. Kos D, Raeymaekers J, Van Remoortel A, D'hooghe MB, Nagels G, D'Haeseleer M, et al. Electronic visual analogue scales
for pain, fatigue, anxiety and quality of life in people with multiple sclerosis using smartphone and tablet: a reliability and
feasibility study. Clin Rehabil 2017 Sep;31(9):1215-1225. [doi: 10.1177/0269215517692641] [Medline: 28786335]
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010
revisions to the McDonald criteria. Ann Neurol 2011 Feb;69(2):292-302 [FREE Full text] [doi: 10.1002/ana.22366] [Medline:
21387374]
15. Smith A. The symbol-digit modalities test: A neuropsychologic test of learning and other cerebral disorders. Seattle: Helmuth
J, editor. Learning disorders. Seattle: Special Child Publications; 1968:83-91.
16. Smith A. Symbol Digits Modalities Test: Manual. Los Angeles: Western Psychological Services; 1982.
17. Rao SM, Losinski G, Mourany L, Schindler D, Mamone B, Reece C, et al. Processing speed test: validation of a
self-administered, iPad-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 2017
Dec;23(14):1929-1937. [doi: 10.1177/1352458516688955] [Medline: 28080262]
18. Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can
J Public Health 1992;83 Suppl 2:S7-S11. [Medline: 1468055]
19. Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions
(FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009 Dec;15(12):1509-1517.
[doi: 10.1177/1352458509348519] [Medline: 19995840]
20. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001
Sep;16(9):606-613 [FREE Full text] [Medline: 11556941]
21. Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale
scores in persons with multiple sclerosis. BMC Neurol 2013 Apr 25;13:37 [FREE Full text] [doi: 10.1186/1471-2377-13-37]
[Medline: 23617555]
22. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric
methods. Health Technol Assess 2009 Feb;13(12):1-177 [FREE Full text] [doi: 10.3310/hta13120] [Medline: 19216837]
23. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new
patient-based outcome measure. Brain 2001 May;124(Pt 5):962-973. [doi: 10.1093/brain/124.5.962] [Medline: 11335698]
24. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and
validity in hospital based samples. J Neurol Neurosurg Psychiatry 2002 Dec;73(6):701-704 [FREE Full text] [doi:
10.1136/jnnp.73.6.701] [Medline: 12438473]
25. Cheng W, Scotland A, Lipsmeier F, Kilchenmann T, Jin L, Schjodt-Eriksen J, et al. Human activity recognition from
sensor-based large-scale continuous monitoring of Parkinson's disease patients. 2017 Presented at: Proceedings of the 2nd
IEEE/ACM International Conference on Connected Health; July 17-19, 2017; Philadelphia. [doi: 10.1109/CHASE.2017.87]
26. Wang Y, Bohannon RW, Kapellusch J, Garg A, Gershon RC. Dexterity as measured with the 9-Hole Peg Test (9-HPT)
across the age span. J Hand Ther 2015;28(1):53-59. [doi: 10.1016/j.jht.2014.09.002] [Medline: 25449717]
27. D'hooghe M, Van Gassen G, Kos D, Bouquiaux O, Cambron M, Decoo D, et al. Improving fatigue in multiple sclerosis
by smartphone-supported energy management: the MS TeleCoach feasibility study. Mult Scler Relat Disord 2018
May;22:90-96 [FREE Full text] [doi: 10.1016/j.msard.2018.03.020] [Medline: 29649789]
Abbreviations
2MWT: Two-Minute Walk Test
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FLAIR:  fluid-attenuated inversion recovery
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PRO:  patient-reported outcome
RMS:  relapsing multiple sclerosis
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